Literature DB >> 26288216

Pharmaceutical Optimization of Peptide Toxins for Ion Channel Targets: Potent, Selective, and Long-Lived Antagonists of Kv1.3.

Justin K Murray, Yi-Xin Qian, Benxian Liu, Robin Elliott, Jennifer Aral, Cynthia Park, Xuxia Zhang, Michael Stenkilsson, Kevin Salyers, Mark Rose, Hongyan Li, Steven Yu, Kristin L Andrews1, Anne Colombero, Jonathan Werner, Kevin Gaida, E Allen Sickmier, Peter Miu, Andrea Itano, Joseph McGivern, Colin V Gegg, John K Sullivan, Les P Miranda.   

Abstract

To realize the medicinal potential of peptide toxins, naturally occurring disulfide-rich peptides, as ion channel antagonists, more efficient pharmaceutical optimization technologies must be developed. Here, we show that the therapeutic properties of multiple cysteine toxin peptides can be rapidly and substantially improved by combining direct chemical strategies with high-throughput electrophysiology. We applied whole-molecule, brute-force, structure-activity analoging to ShK, a peptide toxin from the sea anemone Stichodactyla helianthus that inhibits the voltage-gated potassium ion channel Kv1.3, to effectively discover critical structural changes for 15× selectivity against the closely related neuronal ion channel Kv1.1. Subsequent site-specific polymer conjugation resulted in an exquisitely selective Kv1.3 antagonist (>1000× over Kv1.1) with picomolar functional activity in whole blood and a pharmacokinetic profile suitable for weekly administration in primates. The pharmacological potential of the optimized toxin peptide was demonstrated by potent and sustained inhibition of cytokine secretion from T cells, a therapeutic target for autoimmune diseases, in cynomolgus monkeys.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26288216     DOI: 10.1021/acs.jmedchem.5b00495

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  10 in total

1.  Prolonged immunomodulation in inflammatory arthritis using the selective Kv1.3 channel blocker HsTX1[R14A] and its PEGylated analog.

Authors:  Mark R Tanner; Rajeev B Tajhya; Redwan Huq; Elizabeth J Gehrmann; Kathia E Rodarte; Mustafa A Atik; Raymond S Norton; Michael W Pennington; Christine Beeton
Journal:  Clin Immunol       Date:  2017-04-04       Impact factor: 3.969

2.  Genomic Structure of Two Kv1.3 Channel Blockers from Scorpion Mesobuthus eupeus and Sea Anemone Stichodactyla haddoni and Construction of their Chimeric Peptide as a Novel Blocker.

Authors:  Maryam Asadi; Hoda Ayat; Ali Mohammad Ahadi; Mohammad Sharif Ranjbar
Journal:  Biochem Genet       Date:  2021-07-20       Impact factor: 1.890

Review 3.  Sea Anemones: Quiet Achievers in the Field of Peptide Toxins.

Authors:  Peter J Prentis; Ana Pavasovic; Raymond S Norton
Journal:  Toxins (Basel)       Date:  2018-01-08       Impact factor: 4.546

4.  T Cell Subset and Stimulation Strength-Dependent Modulation of T Cell Activation by Kv1.3 Blockers.

Authors:  Wai-Ping Fung-Leung; Wilson Edwards; Yi Liu; Karen Ngo; Julianty Angsana; Glenda Castro; Nancy Wu; Xuejun Liu; Ronald V Swanson; Alan D Wickenden
Journal:  PLoS One       Date:  2017-01-20       Impact factor: 3.240

5.  Animal protein toxins: origins and therapeutic applications.

Authors:  Na Chen; Siqi Xu; Yuhan Zhang; Feng Wang
Journal:  Biophys Rep       Date:  2018-10-11

6.  A Recurrent Motif: Diversity and Evolution of ShKT Domain Containing Proteins in the Vampire Snail Cumia reticulata.

Authors:  Marco Gerdol; Manuela Cervelli; Paolo Mariottini; Marco Oliverio; Sébastien Dutertre; Maria Vittoria Modica
Journal:  Toxins (Basel)       Date:  2019-02-12       Impact factor: 4.546

7.  Selective Targeting of Nav1.7 with Engineered Spider Venom-Based Peptides.

Authors:  Robert A Neff; Alan D Wickenden
Journal:  Channels (Austin)       Date:  2021-12       Impact factor: 2.581

8.  Kv1.3 Channel Up-Regulation in Peripheral Blood T Lymphocytes of Patients With Multiple Sclerosis.

Authors:  Ioannis Markakis; Ioannis Charitakis; Christine Beeton; Melpomeni Galani; Elpida Repousi; Stella Aggeloglou; Petros P Sfikakis; Michael W Pennington; K George Chandy; Cornelia Poulopoulou
Journal:  Front Pharmacol       Date:  2021-09-23       Impact factor: 5.810

9.  Pharmacological characterization of potent and selective NaV1.7 inhibitors engineered from Chilobrachys jingzhao tarantula venom peptide JzTx-V.

Authors:  Bryan D Moyer; Justin K Murray; Joseph Ligutti; Kristin Andrews; Philippe Favreau; John B Jordan; Josie H Lee; Dong Liu; Jason Long; Kelvin Sham; Licheng Shi; Reto Stöcklin; Bin Wu; Ruoyuan Yin; Violeta Yu; Anruo Zou; Kaustav Biswas; Les P Miranda
Journal:  PLoS One       Date:  2018-05-03       Impact factor: 3.240

Review 10.  Marine Toxins Targeting Kv1 Channels: Pharmacological Tools and Therapeutic Scaffolds.

Authors:  Rocio K Finol-Urdaneta; Aleksandra Belovanovic; Milica Micic-Vicovac; Gemma K Kinsella; Jeffrey R McArthur; Ahmed Al-Sabi
Journal:  Mar Drugs       Date:  2020-03-20       Impact factor: 5.118

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.